China Universal Asset Management Co., Ltd. Prometheus Biosciences, Inc. Transaction History

China Universal Asset Management Co., Ltd.

  • $893 Million
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 21, 2024
BUY
$103.46 - $126.29 $22,554 - $27,531
218 Added 51.17%
644 $69,000
Q1 2023

Apr 27, 2023
BUY
$103.46 - $126.29 $22,554 - $27,531
218 Added 51.17%
644 $69,000
Q4 2022

May 21, 2024
BUY
$36.06 - $117.21 $15,361 - $49,931
426 New
426 $46,000
Q4 2022

Jan 31, 2023
BUY
$36.06 - $117.21 $1,550 - $5,040
43 Added 11.23%
426 $47,000
Q3 2022

Oct 21, 2022
BUY
$28.17 - $59.01 $10,789 - $22,600
383 New
383 $23,000

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email